GSK to begin Phase 3 trial of mRNA seasonal flu vaccine after strong Phase 2 results
read at Endpoints ↗Positive readoutPositive
GSK announced it will start a Phase 3 study of its mRNA vaccine targeting seasonal influenza.
The move follows Phase 2 data that showed the candidate produced higher immune responses than traditional flu shots.
The late‑stage trial will assess safety and efficacy in a larger cohort, aiming to position GSK in the growing mRNA flu vaccine space.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “GSK to launch Phase 3 test of mRNA flu vaccine with newer formulation”
read at Endpoints ↗84 words · retrieved Sep 1
comments(0)
5-min edit window · permanent after that